Trial Profile
A multinational double blind placebo-controlled, parallel group study to evaluate the efficacy and safety of CCX282B in subjects with moderate to severe Crohn's disease.
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2014
At a glance
- Drugs Vercirnon (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROTECT-1
- Sponsors ChemoCentryx
- 10 Jun 2017 Biomarkers information updated
- 20 Oct 2014 Results published in a ChemoCentryx media release.
- 29 Jun 2012 Planned number of patients changed from 423 to 598 as reported by ClinicalTrials.gov.